Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.14
- Piotroski Score 4.00
- Grade Neutral
- Symbol (AGEN)
- Company Agenus Inc.
- Price $3.35
- Changes Percentage (17.13%)
- Change $0.49
- Day Low $2.78
- Day High $3.38
- Year High $19.69
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $9.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $11.60
- Trailing P/E Ratio 1.43
- Forward P/E Ratio 1.43
- P/E Growth 1.43
- Net Income $-245,761,000
Income Statement
Quarterly
Annual
Latest News of AGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Richard Gere Proudly Poses with Wife Alejandra Silva and Son Homer at 'The Agency' Premiere in New York City
Actor Richard Gere, 75, attended the NYC premiere of his show "The Agency" with his wife Alejandra Silva, 41, and son Homer, 24. They were joined by co-stars Michael Fassbender, Jodie Turner-Smith, an...
By PEOPLE.com | 11 hours ago -
US agency votes to launch review, update undersea telecommunications cable rules
By David ShepardsonWASHINGTON (Reuters) - The Federal Communications Commission voted on Thursday to propose new rules governing undersea internet cables in the face of growing security concerns, ...
By Reuters | 16 hours ago -
MLB free agency odds: Favorites to land top free agents Soto, Burnes, and more
Teams are already strategizing to attract top free agents for the 2025 MLB season. With players waiting for suitable contracts, a competitive free agency period is expected, featuring big names like J...
By USA Today | 20 hours ago
